Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Orexigen Therapeutics, Inc. Pockets $100 Million Milestone Payment From Takeda Pharmaceutical Co. Ltd.

October 15, 2014 – 5:00 am | Edit Post

Milestone Payments Earned by Orexigen Total $100 Million as Contrave (naltrexone HCI and bupropion HCI extended release) is Shipped to Wholesalers in Preparation for Commercial LaunchSAN DIEGO, Oct. 15, 2014 /PRNewswire/ — Orexigen Therapeutics, Inc. (Nasdaq:OREX) today announced…

Announcement Regarding Submission Of Tender Offer For Shares In Ambit Biosciences

October 15, 2014 – 5:00 am | Edit Post

TOKYO and SAN DIEGO, Oct. 14, 2014 /PRNewswire/ –On Friday October 10, U.S. Eastern Time, Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) (TSE: 4568), through its wholly-owned U.S. subsidiary, Charge Acquisition Corp., launched a tender…

Inogen To Announce Third Quarter 2014 Results On Tuesday, November 11, 2014

October 15, 2014 – 5:00 am | Edit Post

GOLETA, Calif., Oct. 14, 2014 (GLOBE NEWSWIRE) — Inogen, Inc. (Nasdaq:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release its financial results for the third quarter of 2014 after the close of trading on Tuesday…

San Diego???s Flourishing Industrial Biotech Sector Provides The Backdrop ForBiotechnology Industry Organization (BIO)???s 2014 Pacific Rim Summit On Industrial Biotech & Bioenergy

October 15, 2014 – 5:00 am | Edit Post

With a growing industrial biotech sector that is home to more than 400 biotechnology companies, San Diego is set to host BIOs 2014 Pacific Rim Summit on Industrial Biotech & Bioenergy. San Diego-based industrial biotechnology companies continue to deliver next generation products and innovative technology solutions, many of which will be highlighted during the programming at this years Summit. The…

UBS: Gilead Sciences, Inc. Remains Solid Buy Despite Irish Tax Changes, Price War

October 15, 2014 – 5:00 am | Edit Post

Illumina, Inc. Picks Three Companies For Accelerator Funding Cycle

October 15, 2014 – 5:00 am | Edit Post

Illumina Accelerator Announces Investment in Inaugural Startup ClassInitial Companies Focused on Breakthrough Applications in Therapeutics, Agriculture, and Molecular PathologySAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (ILMN) today announced the selection of three startup companies for the inaugural Illumina Accelerator funding cycle. The…

San Diego’s Ebola-fighting efforts expand

October 14, 2014 – 10:20 pm | Edit Post

Yet another Ebola-fighting product has emerged from San Diego, a blood purifier.

San Diego’s Ebola-fighting efforts expand

October 14, 2014 – 10:20 pm | Edit Post

Yet another Ebola-fighting product has emerged from San Diego, a blood purifier.

DNAtrix Completes $20 Million Series B Financing

October 14, 2014 – 6:00 am | Edit Post

SAN DIEGO, Oct. 14, 2014 /PRNewswire/ — DNAtrix, a clinical-stage oncolytic immunotherapy company, announced that it has completed a $20M Series B equity financing.  New investor Morningside Ventures led the round and was joined by existing investors including Mercury Fund, Targeted Technology Fund and others.  Ms. Reenie McCarthy has joined the DNAtrix Board of Directors for Morningside.

“Securing this funding is a significant milestone that will enable us to advance our lead oncolytic virus product, DNX-2401, into late stage clinical trials for glioblastoma,” said Frank Tufaro, Ph.D., president and chief executive officer of DNAtrix.  “We have encouraging results from four completed and ongoing clinical studies, and this over-subscribed funding round validates our data-driven clinical approach.”  DNAtrix previously reported the outcome of a Phase 1 clinical study of DNX-2401 in 37 recurrent glioblastoma patients that showed durable tumor responses and long- term benefit in a significant subset of patients.

“We are pleased to work with DNAtrix to address this critical need,” said Reenie McCarthy, for Morningside.  “As long-time believers in the potential of oncolytics, we are gratified to see this promising treatment progress for this unmet medical need.” 

About Morningside Morningside is a diversified investment group founded in 1986 by the Chan family of Hong Kong. It is engaged primarily in private equity and venture capital investments. The group has investments in North America, Europe, across Asia-Pacific, and since 1992, in Mainland China. Morningside is an active investor in early-stage life science companies formed around new technologies that represent a high degree of novelty over existing technologies. More information is available at www.morningside.com.

About Mercury Fund, Inc. Mercury Fund is a seed-stage venture capital firm that makes equity investments in compelling and novel software and science-based startup opportunities. Since inception in 2005, Mercury Fund has become one of the most active seed-stage venture firms in the Midcontinent.

About DNAtrix, Inc. DNAtrix is a company developing modified viruses for the treatment of the most aggressive forms of cancer. Since viruses are already efficient at killing cells, scientists have harnessed this ability by modifying a common cold virus so that it targets and selectively kills cancer cells. DNAtrix is a privately held company located in Houston, Texas and San Diego, California. For more information, please visit the Company’s website at http://www.dnatrix.com.

Contact: Frank Tufaro, Ph.D. Chief Executive Officer ftufaro@dnatrix.com 
SOURCE DNAtrix, Inc.

BioAtla Receives Broad Patent For Antibody Development

October 14, 2014 – 5:30 am | Edit Post

SAN DIEGO, Oct. 14, 2014 /PRNewswire/ – BioAtla, a global biotechnology company focused on the development of Conditionally Active Biologics (CABs), today announced that the United States Patent and Trademark Office (USPTO) has issued to BioAtla U.S. Patent No. 8,859,467, for its proprietary Comprehensive Integrated Antibody Optimization™ (CIAO!™) technology platform. The BioAtla CIAO patent broadly covers methods of evolving and screening for antibodies in manufacturing host cells during the discovery stages of drug development. The CIAO technology platform allows for antibody candidate development in a native cellular environment that generates the best collection of lead candidates that optimize downstream expression yields and in vivo translation of function, thereby increasing the likelihood of preserving selected therapeutic activities in the final drug.

“CIAO and our related proprietary evolution and selection technologies are beneficial, and often critical, in the development of antibodies and other proteins that maximize selectivity, such as those developed from our patented CAB technology,” said Jay M. Short, Ph.D., president, chief executive officer and chairman of the board of BioAtla. “CABs can be designed as monoclonal antibodies, antibody drug conjugates (ADCs), CAR-T cells or other therapeutics to target specific tissues in cancerous or distressed conditions associated with unique microenvironments in the body. CAB antibodies are a disruptive technology for the development of a powerful new class of immunotherapeutics and are prime examples of novel potential product opportunities that benefit from the use of CIAO-based processes.”

BioAtla employs CIAO technology in all of its internal development programs for its growing list of pipeline antibody candidates. The high fidelity of the CIAO platform when combined with BioAtla’s evolution technologies allows selection of therapeutic candidates with unique functional characteristics, natural protein folding and glycosylation, high protein expression and faster downstream process development characteristics, all of which enable cost and time efficiencies, as well as maximizing and preserving functionality. This homogenous process of evolution through manufacturing leads to greater predictability and likelihood of therapeutic success. BioAtla has successfully utilized CIAO in dozens of antibody programs it has conducted for biotechnology companies and research institutions over the past several years including the licensing in early 2014 of an antibody directed at a novel validated target for the treatment of inflammatory bowel diseases (IBD) and colorectal cancer.

About the CIAO! Technology Platform The development of novel therapeutic antibodies is increasingly employing the power of evolution to discover molecules with selected characteristics. A molecule’s characteristics reflect all inherent and environmental influences such as amino acid sequence, secondary modifications (e.g. glycosylation), and tertiary characteristics such as folding which is affected by environmental factors including pH, salt, temperature, hydrophobicity, support proteins (e.g. chaperonins), substrate pools; generically, the host environment. While the power of evolution is the ability to discover molecules with selected characteristics, the inherent challenge is that the selection process is dominated by the selection environment or assay. As an example, selecting a molecule in bacteria and subsequently expressing in mammalian cells risks generating molecules that require extra process development costs to adapt to the different host system and poor pK in vivo due to the potential of selecting unnatural secondary and tertiary structures. The power of BioAtla’s CIAO technology is that it selects molecules in a manner that mirrors both the body’s environment and the host that will be used for final manufacturing of the drug.

About Conditionally Active Biologics (CABs)Conditionally Active Biologic proteins (CABs) are generated using BioAtla’s proprietary protein evolution technologies, including CIAO, that typically employ selected amino acid substitutions in a protein that work together to confer selective conditional activation found in a range of microenvironments existing in the body. These proteins can be monoclonal antibodies (mAbs), antibody drug conjugates, CAR-T cells, or other therapeutic proteins designed with functions dependent on changes in microphysiological conditions (e.g., pH, oxidation, temperature, pressure, presence of certain ions, hydrophobicity and combinations thereof).

CABs allow for higher dosing or the development of more potent, non-immunogenic drugs. CABs increase safety because the drug is activated and preferentially binds directly to its intended target protein in the microenvironment of the diseased cells and not in normal tissue.  This advantage allows CABs to use targets that are present on cancer cells even though the targets may also be prevalent among normal cells. Such targets are considered unusable in current drug therapy approaches because their lack of selectivity risks unwanted on-target toxicity. The higher selectivity resulting from CAB antibody generation is expected to capitalize on the attractiveness of such previously unavailable targets and increase the effectiveness of most therapeutics relative to traditional antibody approaches.

About BioAtla, LLCBioAtla is a global biotechnology company with operations in San Diego, California, and Beijing, China. BioAtla develops novel monoclonal antibody and other protein therapeutic products with more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing. By utilizing its proprietary technologies of product design and development, from target discovery to manufacturing and preclinical studies, BioAtla develops differentiated, patentable therapeutic proteins for its partners and for its internal programs. BioAtla has over 70 patents issued and pending that cover its platform technologies representing a full complement of therapeutic protein development capabilities. Learn more at www.bioatla.com.
SOURCE BioAtla